IRLAB Therapeutics ABOSTO:IRLAB A +0.16%35 Interest Coverage is 5.54 as of Mar. 2026, which is 96% below its 10-year median of 141.76. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 35/100 and a GF Value™ of kr11.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 377 Biotechnology companies, IRLAB Therapeutics AB ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. IRLAB Therapeutics AB's
Operating Income
for the
three
months ended in Mar. 2026 was kr10.73 Mil. IRLAB Therapeutics AB's Interest Expense for the
three
months ended in Mar. 2026 was kr-1.94 Mil.
IRLAB Therapeutics AB's interest coverage for the quarter that ended in Mar. 2026 was 5.54.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for IRLAB Therapeutics AB's Interest Coverage or its related term are showing as below:
OSTO:IRLAB A's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
IRLAB Therapeutics AB (OSTO:IRLAB A) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
IRLAB Therapeutics AB Interest Coverage Related Terms
IRLAB Therapeutics AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for IRLAB Therapeutics AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OSTO:IRLAB A vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's Interest Coverage falls into.
IRLAB Therapeutics AB Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Interest Coverage of 5.54 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IRLAB Therapeutics AB and its competitors. This is 96% below median its historical median of 141.76. According to the industry distribution chart, IRLAB Therapeutics AB ranks #999999 out of 377 companies in the Biotechnology industry.
Is IRLAB Therapeutics AB's Interest Coverage too high?
IRLAB Therapeutics AB's current Interest Coverage of 5.54 is 96% below median its 10-year median of 141.76. The Biotechnology industry median Interest Coverage is 106.07. IRLAB Therapeutics AB's value of 5.54 is 94.8% below this industry median. Based on the distribution chart, IRLAB Therapeutics AB ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IRLAB Therapeutics AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #999999 out of 377 companies for Interest Coverage. This places IRLAB Therapeutics AB in the lower half of its industry. The industry median Interest Coverage is 106.07. IRLAB Therapeutics AB's value of 5.54 is 94.8% below this benchmark. While the company's 10-year median is 141.76 vs. the industry median of 106.07, IRLAB Therapeutics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IRLAB Therapeutics AB's current Interest Coverage of 5.54 is 94.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current Interest Coverage is 5.54, which is 96% below median its own 10-year median of 141.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.78, compared to a current price of kr1.22 — trading 89.6% below its estimated fair value. The current Interest Coverage is 5.54, which is 96% below median its 10-year median of 141.76 and 94.8% below the Biotechnology industry median of 106.07. IRLAB Therapeutics AB's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Interest Coverage is 5.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.22 is trading 89.6% below its estimated GF Value™ of kr11.78.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
Interest Coverage: 5.54 (96% below median its 10-year median of 141.76)
GF Value™: kr11.78 vs. price of kr1.22 (89.6% below fair value)
Industry Position: 94.8% below the Biotechnology median (#999999 of 377)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
35GF Score
Get the complete analysis for OSTO:IRLAB A
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
